For the clinical study with immunotherapy, the literature indicated that nivolumab (anti-PD-1) has anti-tumor efficacy and safety in patients with GC, which is delivered as maintenance treatment (after the illness is under control with conventional chemotherapy) (72). This evidence concerns the gene PDCD1 and gastric cancer.